Normalisation of high CA 19-9 values in autoimmune hepatitis after steroidal treatment

International Journal of Immunopathology and Pharmacology

Volumn 18, Issue 3, 2005, Pages 603-607

  Montalto, Massimo ^a   Santoro, L ^a   Vastola, M ^a   Curigliano, V ^a   Ricci, R ^a   Vecchio, F M ^a   Manna, R ^a   Gasbarrini, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Autoimmune hepatitis; CA 19 9; Treatment

Indexed keywords

CA 19-9 ANTIGEN; KI 67 ANTIGEN; METHYLPREDNISOLONE; STEROID;

ADULT; ARTICLE; AUTOIMMUNE HEPATITIS; BILE DUCT; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LABORATORY TEST; LIVER BIOPSY; LIVER CELL; METAPLASIA; PRIORITY JOURNAL;

EID: 27444447413     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200501800321     Document Type: Article

References (14)

1. Haglund C., J. Lundin, P. Kuusela and P.J. Roberts. 1994. CA242, a new tumour marker for pancreatic cancer. A comparison with CA19-9, CA50 and CEA. Br. J. Cancer 70:487.
2. Kitagawa Y., M. Iwai, A. Muramatsu, S. Tanaka, T. Mori, Y. Harada, T. Okanoue and K. Kashima. 2002 Immunohistochemical localization of CEA, CA19-9 and DU-PAN-2 in hepatitis C virus-infected liver tissues. Histopathology 40:472.
3. Maestranzi S., R. Przemioslo, H. Mitchell and R.A. Sherwood. 1998. The effect of benign and malignant liver disease on the tumour markers CA19-9 and CEA. Ann. Clin. Biochem. 35:99.
4. Katsanos K.H., M. Kitsanou, D.K. Christodoulou and E.V. Tsianos. 2002. High CA 19-9 levels in benign tract diseases. Report of four cases and review of the literature. Eur. J. Intern. Med. 13:132.
5. Alvarez F., P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, E.L. Cancado, et al. 1999. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J. Hepatol. 31:929.
6. Czaja A.J. 1995. Autoimmune hepatitis: evolving concepts and treatment strategies. Dig. Dis. Sci. 40:435.
7. Johnson P.J. and I.G. McFarlane. 1993. Meeting report: International Autoimmune Hepatitis Group. Hepatology 18:998.
8. Wies I., S. Brunner, J. Henninger, J. Herkel, S. Kanzler, K.H. Meyer zum Buschenfelde and A.W. Lohse. 2000. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 355:1510.
9. Muratori L., M. Cataleta, P. Muratori, M. Lenzi and F.B. Bianchi. 1998. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 42:721.
10. Sohda T., Y. Iwata, H. Shijo, Y. Egashira, K. Egashira and M. Okumura. 1998. Increased expression of proliferating cell nuclear antigen in autoimmune hepatitis in a patient with raised serum concentration of CA19-9. J. Clin. Pathol. 51:167.
11. Halme L., P. Karkkainen, H. Isoniemi, H. Makisalo, K. von Bogulawski and K. Hockerstedt. 1999. Carbohydrate 19-9 antigen as a marker of non-malignant hepatocytic ductular transformation in patients with acute liver failure. A comparison with alpha-fetoprotein and carcinoembryonic antigen. Scand. J. Gastroenterol. 34:426.
12. Mano Y., M. Ishii, H. Okamoto, T. Igarashi, K. Kobayashi and T. Toyota. 1996. Effect of tumor necrosis factor α on intrahepatic bile duct epithelial cells of rat liver. Hepatology 23:1602.
13. Collazos J., J. Genolla and A. Ruibal. 1992. CA 19-9 in non-neoplastic liver diseases. A clinical and laboratory study. Clin. Chim. Acta 210:145.
14. Thomas P. and N. Zamcheck. 1983. Role of liver in clearance and excretion of circulating carcinoembryonic antigen (CEA). Dig. Dis. Sci. 28:216.